PharmaEssentia Corporation
6446
Pozycja w akcjach
#1423
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Cena akcji
$37.84
Kapitalizacja rynkowa
$15.65B
Zmiana (1 dzień)
-4.42%
Zmiana (1 rok)
149.23%
Kraj
TW
Handel PharmaEssentia Corporation (6446)
Kategoria
Healthcare
EPS dla PharmaEssentia Corporation (6446)
EPS na dzień June 2026 TTM: $0.63
Według najnowszych raportów finansowych i ceny akcji firmy PharmaEssentia Corporation, obecny EPS (TTM) wynosi $0.63. Na koniec roku 2023 firma miała EPS w wysokości $-0.06, spadek w porównaniu do do EPS z roku 2022, który wynosił $-0.14.
Historia EPS dla PharmaEssentia Corporation od 2010 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.63 | 153.00% |
| 2024 | $0.25 | -534.22% |
| 2023 | $-0.06 | -60.15% |
| 2022 | $-0.14 | -59.50% |
| 2021 | $-0.35 | 37.91% |
| 2020 | $-0.25 | 119.47% |
| 2019 | $-0.12 | -14.95% |
| 2018 | $-0.14 | 15.09% |
| 2017 | $-0.12 | 5.89% |
| 2016 | $-0.11 | -6.67% |
| 2015 | $-0.12 | -4.08% |
| 2014 | $-0.13 | 25.60% |
| 2013 | $-0.10 | 63.82% |
| 2012 | $-0.06 | 25.36% |
| 2011 | $-0.05 | 16.87% |
| 2010 | $-0.04 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -12.05% |
IN
|
